Compare FDP & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDP | PHVS |
|---|---|---|
| Founded | 1886 | 2015 |
| Country | Cayman Islands | Switzerland |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 1999 | 2020 |
| Metric | FDP | PHVS |
|---|---|---|
| Price | $32.63 | $28.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $41.82 |
| AVG Volume (30 Days) | 291.9K | ★ 373.3K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $4,322,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | $156.14 | ★ N/A |
| Revenue Growth | ★ 0.98 | N/A |
| 52 Week Low | $31.85 | $15.51 |
| 52 Week High | $43.58 | $33.33 |
| Indicator | FDP | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 17.23 | 46.46 |
| Support Level | $32.40 | $24.73 |
| Resistance Level | $36.48 | $28.72 |
| Average True Range (ATR) | 1.47 | 1.65 |
| MACD | -0.67 | -0.21 |
| Stochastic Oscillator | 1.67 | 7.20 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.